Second- and third-generation drug-eluting coronary stents: progress and safety.

PubWeight™: 0.93‹?›

🔗 View Article (PMID 21505934)

Published in Herz on May 01, 2011

Authors

I Akin1, H Schneider, H Ince, S Kische, T C Rehders, T Chatterjee, C A Nienaber

Author Affiliations

1: Heart Center RostockDepartment of Internal Medicine I, University Hospital Rostock, Deutschland.

Articles cited by this

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81

Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol (2006) 8.27

Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol (2006) 6.07

Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77

Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation (2004) 5.44

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37

Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med (2007) 4.95

Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet (2010) 4.87

Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med (2010) 3.27

Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet (2007) 3.20

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12

Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA (2008) 2.59

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet (2008) 2.57

Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol (2008) 2.45

Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation (2009) 2.40

Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet (2010) 2.38

Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation (2001) 2.34

Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation (2005) 1.90

Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol (2008) 1.84

A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol (2010) 1.80

An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J (2009) 1.79

Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med (2010) 1.70

Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation (2006) 1.62

Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol (2006) 1.56

Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. J Am Coll Cardiol (2008) 1.48

Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. Catheter Cardiovasc Interv (2008) 1.46

Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Catheter Cardiovasc Interv (2010) 1.43

A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention (2005) 1.42

3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv (2009) 1.26

Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation (2002) 1.21

Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation (2006) 1.13

Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation (2007) 1.11

Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention (2010) 0.99

Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry). Am J Cardiol (2009) 0.93

Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ Cardiovasc Interv (2009) 0.92

Angioscopic comparison of neointimal coverage between zotarolimus- and sirolimus-eluting stents. J Am Coll Cardiol (2008) 0.91

Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI). Circ Cardiovasc Interv (2010) 0.90

The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention (2007) 0.89

First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention (2005) 0.88

Frequency and clinical consequences associated with sidebranch occlusion during stent implantation using zotarolimus-eluting and paclitaxel-eluting coronary stents. Circ Cardiovasc Interv (2009) 0.82

Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2). JACC Cardiovasc Interv (2010) 0.82

Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am Heart J (2009) 0.79

Everolimus or paclitaxel stents in real life: go COMPARE. Lancet (2010) 0.75

Articles by these authors

EPITHELIAL CELL PENETRATION AS AN ESSENTIAL STEP IN THE PATHOGENESIS OF BACILLARY DYSENTERY. J Bacteriol (1964) 19.60

The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA (2000) 12.26

Rescue of measles viruses from cloned DNA. EMBO J (1995) 7.87

Toward a phylogenetic classification of Primates based on DNA evidence complemented by fossil evidence. Mol Phylogenet Evol (1998) 5.55

Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90

Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation (2000) 3.75

Horsetails and ferns are a monophyletic group and the closest living relatives to seed plants. Nature (2001) 3.64

Heterogeneity of molecular size and antigenic expression within lipooligosaccharides of individual strains of Neisseria gonorrhoeae and Neisseria meningitidis. Infect Immun (1984) 3.33

Fermentation of a pentose by yeasts. Biochem Biophys Res Commun (1980) 3.09

Clinical prediction of acute aortic dissection. Arch Intern Med (2000) 2.81

The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity (2000) 2.70

Immunological basis of serum resistance of Neisseria gonorrhoeae. J Gen Microbiol (1982) 2.66

Mitochondrial protein import: identification of processing peptidase and of PEP, a processing enhancing protein. Cell (1988) 2.57

Snoring and sleep apnea. A population study in Australian men. Am J Respir Crit Care Med (1995) 2.56

Antigenic and physical diversity of Neisseria gonorrhoeae lipooligosaccharides. Infect Immun (1986) 2.55

Fermentation of D-xylose, xylitol, and D-xylulose by yeasts. Can J Microbiol (1982) 2.50

Phenotypic variation in epitope expression of the Neisseria gonorrhoeae lipooligosaccharide. Infect Immun (1987) 2.34

Importance of dural ectasia in phenotypic assessment of Marfan's syndrome. Lancet (1999) 2.20

Rescue of synthetic measles virus minireplicons: measles genomic termini direct efficient expression and propagation of a reporter gene. Virology (1995) 2.11

[Guideline-conforming interventional treatment of acute ST-segment elevation myocardial infarction in rural areas using network collaboration]. Dtsch Med Wochenschr (2004) 2.11

Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. J Virol (1988) 2.09

Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am J Obstet Gynecol (1972) 1.98

The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem (1999) 1.97

Dynamic behavior of fluorescent probes in lipid bilayer model membranes. Biochemistry (1973) 1.97

Surgical management of complications after transcatheter closure of an atrial septal defect or patent foramen ovale. J Thorac Cardiovasc Surg (2000) 1.94

Elaboration of a 3.6-kilodalton lipooligosaccharide, antibody against which is absent from human sera, is associated with serum resistance of Neisseria gonorrhoeae. Infect Immun (1985) 1.93

Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J (1999) 1.83

Acute aortic dissection: perspectives from the International Registry of Acute Aortic Dissection (IRAD). Eur J Vasc Endovasc Surg (2008) 1.80

Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol (1996) 1.79

Partially hydrolyzed guar gum-supplemented oral rehydration solution in the treatment of acute diarrhea in children. J Pediatr Gastroenterol Nutr (2000) 1.68

Physical heterogeneity of neisserial lipooligosaccharides reflects oligosaccharides that differ in apparent molecular weight, chemical composition, and antigenic expression. Infect Immun (1987) 1.67

The mitochondrial receptor complex: a central role of MOM22 in mediating preprotein transfer from receptors to the general insertion pore. Cell (1993) 1.67

Bactericidal antibody response of normal human serum to the lipooligosaccharide of Neisseria gonorrhoeae. J Infect Dis (1986) 1.66

Isolation and characterization of lipopolysaccharides, lipooligosaccharides, and lipid A. Methods Enzymol (1994) 1.64

Expression of measles virus V protein is associated with pathogenicity and control of viral RNA synthesis. J Virol (1998) 1.63

Recombinant measles viruses with mutations in the C, V, or F gene have altered growth phenotypes in vivo. J Virol (1998) 1.62

Induction of Cellulolytic and Xylanolytic Enzyme Systems in Streptomyces spp. Appl Environ Microbiol (1987) 1.61

Pelvimetry by magnetic resonance imaging as a diagnostic tool to evaluate dystocia. Obstet Gynecol (1997) 1.59

Liposome-mitochondrial inner membrane fusion. Lateral diffusion of integral electron transfer components. J Biol Chem (1980) 1.56

Cheaper antiretrovirals to treat AIDS in South Africa. They are at their most cost effective in preventing mother to child transmission. BMJ (2000) 1.54

Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther (2003) 1.52

Abbreviated method for assessing upper airway function in obstructive sleep apnea. Chest (2000) 1.52

Meningococcal infections. 1. Prevalence of serogroups causing disease in US Army personnel in 1964-70. Bull World Health Organ (1971) 1.50

Structural determination of oligosaccharides derived from lipooligosaccharide of Neisseria gonorrhoeae F62 by chemical, enzymatic, and two-dimensional NMR methods. Biochemistry (1991) 1.49

Inflammatory cytokines produced in response to experimental human gonorrhea. J Infect Dis (1995) 1.49

Ventilating with tracheal gas insufflation and periodic tracheal occlusion during sleep and wakefulness. Chest (2002) 1.48

Anoxic encephalopathy with predominant involvement of basal ganglia, brain stem and spinal cord in the perinatal period. Report on seven newborns. Acta Neuropathol (1975) 1.46

Solute balance of a maize (Zea mays L.) source leaf as affected by salt treatment with special emphasis on phloem retranslocation and ion leaching. J Exp Bot (2000) 1.46

Voltage- and transmitter-gated currents of all-amacrine cells in a slice preparation of the rat retina. J Neurosci (1993) 1.45

Interleukin-6: a cytokine to forget. FASEB J (2004) 1.45

Cardiac manifestation of the hypereosinophilic syndrome: new insights. Clin Res Cardiol (2010) 1.45

Glutamate responses of bipolar cells in a slice preparation of the rat retina. J Neurosci (1996) 1.44

Successful expression of beta-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein. Gene Ther (1999) 1.43

Importance of sympathetic activation for the expression of Na+-Ca2+ exchanger in end-stage failing human myocardium. Eur Heart J (2002) 1.43

A bactericidal microassay for testing serum sensitivity of Neisseria gonorrhoeae. J Immunol Methods (1982) 1.42

Structure and heterogeneity of the oligosaccharides from the lipopolysaccharides of a pyocin-resistant Neisseria gonorrhoeae. Proc Natl Acad Sci U S A (1989) 1.41

Epitope expression and partial structural characterization of F62 lipooligosaccharide (LOS) of Neisseria gonorrhoeae: IgM monoclonal antibodies (3F11 and 1-1-M) recognize non-reducing termini of the LOS components. Mol Immunol (1991) 1.40

Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J (2000) 1.40

A mouse organotypic tissue culture model for autosomal recessive congenital ichthyosis. Br J Dermatol (2014) 1.40

Preservation of regional myocardial function and myocardial oxygen tension during acute ischemia in pigs: comparison of selective synchronized suction and retroinfusion of coronary veins to synchronized coronary venous retroperfusion. J Am Coll Cardiol (1994) 1.39

Lipooligosaccharides: the principal glycolipids of the neisserial outer membrane. Rev Infect Dis (1988) 1.38

[Angina pectoris in normal coronary arteries (microvascular angina/syndrome X)]. Dtsch Med Wochenschr (1997) 1.38

[Hematothorax after sudden chest pain]. Dtsch Med Wochenschr (2006) 1.38

[Contrast-media-induced nephrotoxicity]. Dtsch Med Wochenschr (2005) 1.37

The effect of D2-O on the thermal stability of proteins. Thermodynamic parameters for the transfer of model compounds from H2-O to D2-O. J Phys Chem (1965) 1.34

The effects of alcohols on lipid bilayers: a spin label study. Biochim Biophys Acta (1972) 1.33

Haemoglobin interferes with the ex vivo luciferase luminescence assay: consequence for detection of luciferase reporter gene expression in vivo. Gene Ther (2000) 1.33

Mutants of Pachysolen tannophilus with Improved Production of Ethanol from d-Xylose. Appl Environ Microbiol (1986) 1.31

Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med (1989) 1.30

"Real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multi-centre German Cypher Registry. Z Kardiol (2004) 1.28

Production and degradation of serogroup B Neisseria meningitidis polysaccharide. Infect Immun (1972) 1.27

Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. Pediatrics (1983) 1.27

The membrane concentrations of alcohol anesthetics. Biochim Biophys Acta (1971) 1.27

Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation. Immunity (1995) 1.26

Stability of expression of Neisseria gonorrhoeae lipooligosaccharides. Infect Immun (1986) 1.25

Spin label studies of oriented phospholipids: egg lecithin. Biochim Biophys Acta (1970) 1.24

Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther (2003) 1.23

Use of transformation to construct Neisseria gonorrhoeae strains with altered lipooligosaccharides. Infect Immun (1988) 1.22

Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function. J Exp Med (2001) 1.21

Characterization of a structural series of lipid A obtained from the lipopolysaccharides of Neisseria gonorrhoeae. Combined laser desorption and fast atom bombardment mass spectral analysis of high performance liquid chromatography-purified dimethyl derivatives. J Biol Chem (1986) 1.21

Isolation and characterization of disc-shaped phycobilisomes from the red alga Rhodella violacea. Arch Microbiol (1977) 1.20

Lysis of Neisseria gonorrhoeae initiated by binding of normal human IgM to a hexosamine-containing lipooligosaccharide epitope(s) is augmented by strain-specific, properdin-binding-dependent alternative complement pathway activation. J Immunol (1991) 1.20

Utilization of Xylan by Yeasts and Its Conversion to Ethanol by Pichia stipitis Strains. Appl Environ Microbiol (1986) 1.19

Fusion of liposomes with mitochondrial inner membranes. Proc Natl Acad Sci U S A (1980) 1.19

The cytochrome b gene as a phylogenetic marker: the limits of resolution for analyzing relationships among cichlid fishes. J Mol Evol (2001) 1.18

Origins and antiquity of X-linked triallelic color vision systems in New World monkeys. Proc Natl Acad Sci U S A (1998) 1.18

Some Properties of Extracellular Acetylxylan Esterase Produced by the Yeast Rhodotorula mucilaginosa. Appl Environ Microbiol (1987) 1.17

Mitochondrial DNA phylogeny of the family Cichlidae: monophyly and fast molecular evolution of the neotropical assemblage. J Mol Evol (1999) 1.16

Patterns and implications of medical pluralism among HIV/AIDS patients in rural South Africa. AIDS Behav (2011) 1.15